Symptomtext
vaccine Fluzone QIV NP was given during a temperature excursion with no reported adverse event; vaccine Fluzone QIV NP was given during a temperature excursion with no reported adverse event; Initial information received on 11-Feb-2022 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 38 years old female patient who had experienced an event vaccine Influenza Quadrival a-b vaccine [Fluzone quadrivalent] was given during a temperature excursion with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect influenza quadrival a-b vaccine at a dose of 0.5 mL (lot UT7383KA; Expiration Date :2022-06-30) (strength, formulation: not reported) via intramuscular route in unknown administration site for immunization. On an unknown date the patient developed a non-serious vaccine fluzone qiv np was given during a temperature excursion with no reported adverse event (product temperature excursion issue) (product administration error) (unknown latency) following the administration of Influenza quadrival a-b vaccine. Action taken: not applicable. At time of reporting, the outcome was unknown for the events product temperature excursion issue , product administration error. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.